دورية أكاديمية
Prediction of outcomes in patients with ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance
| العنوان: | Prediction of outcomes in patients with ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance |
|---|---|
| المؤلفون: | Jabbour, E, le Coutre, P D, Cortes, J, Giles, F, Bhalla, K N, Pinilla-Ibarz, J, Larson, R A, Gattermann, N, Ottmann, O G, Hochhaus, A, Hughes, T P, Saglio, G, Radich, J P, Kim, D-W, Martinelli, G, Reynolds, J, Woodman, R C, Baccarani, M, Kantarjian, H M |
| بيانات النشر: | Springer Nature |
| سنة النشر: | 2012 |
| المجموعة: | National University of Ireland (NUI), Galway: ARAN |
| مصطلحات موضوعية: | chronic myeloid leukemia, nilotinib, multivariate analysis, predictive model, imatinib intolerance, imatinib resistance, chronic myelogenous leukemia, tyrosine kinase inhibitors, interferon-alpha, tumor response, failure, survival, mesylate, resistance, time |
| الوصف: | The purpose was to assess predictive factors for outcome in patients with chronic myeloid leukemia (CML) in chronic phase (CML-CP) treated with nilotinib after imatinib failure. Imatinib-resistant and -intolerant patients with CML-CP (n = 321) were treated with nilotinib 400 mg twice daily. Of 19 baseline patient and disease characteristics and two response end points analyzed, 10 independent prognostic factors were associated with progression-free survival (PFS). In the multivariate analysis, major cytogenetic response (MCyR) within 12 months, baseline hemoglobin >= 120 g/l, baseline basophils <4%, and absence of baseline mutations with low sensitivity to nilotinib were associated with PFS. A prognostic score was created to stratify patients into five groups (best group: 0 of 3 unfavorable risk factors and MCyR by 12 months; worst group: 3 of 3 unfavorable risk factors and no MCyR by 12 months). Estimated 24-month PFS rates were 90%, 79%, 67% and 37% for patients with prognostic scores of 0, 1, 2 and 3, respectively, (no patients with score of 4). Even in the presence of poor disease characteristics, nilotinib provided significant clinical benefit in patients with imatinib-resistant or -intolerant CML. This system may yield insight on the prognosis of patients. Leukemia (2013) 27, 907-913; doi:10.1038/leu.2012.305 |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | unknown |
| العلاقة: | Leukemia; Jabbour, E; le Coutre, P D; Cortes, J; Giles, F; Bhalla, K N; Pinilla-Ibarz, J; Larson, R A; Gattermann, N; Ottmann, O G; Hochhaus, A; Hughes, T P; Saglio, G; Radich, J P; Kim, D-W; Martinelli, G; Reynolds, J; Woodman, R C; Baccarani, M; Kantarjian, H M (2012). Prediction of outcomes in patients with ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia 27 (4), 907-913; 0887-6924,1476-5551; http://hdl.handle.net/10379/12051Test |
| DOI: | 10.1038/leu.2012.305 |
| الإتاحة: | https://doi.org/10.1038/leu.2012.305Test http://hdl.handle.net/10379/12051Test |
| حقوق: | Attribution-NonCommercial-NoDerivs 3.0 Ireland ; https://creativecommons.org/licenses/by-nc-nd/3.0/ieTest/ |
| رقم الانضمام: | edsbas.D808DCE8 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1038/leu.2012.305 |
|---|